

PrimeC As a Promising Therapeutic Candidate for ALS Alon Ben-Noon, Shiran Zimri, Niva Russek-Blum, Diana Shtossel, Ferenc Tracik Company name NeuroSense Therapeutics *

Website <https://www.neurosensetx.com/>* CEO name: Alon Ben-Noon Cell

CATEGORY: Biotech/Pharma* • Israeli medical contribution to breakthrough science and technology PrimeC as a Promising Therapeutic Candidate for ALS

o Executive Summary / Investment Rational NeuroSense's leading therapeutic solution, PrimeC, is an innovative combination compound addressing multiple pathologies associated with ALS, an indication with an annual market valuation estimated at \$3-4B USD. NeuroSense successfully completed a phase 2b trial with top-line results and additional clinical outcomes that shows great promise for affecting the disease progression meaningfully, alongside clinical phases for AD and preclinical work for PD. NeuroSense has partnered with leading players in the ALS space.

o Core Technology What is the technology, its uniqueness, and its value proposition? Our flagship therapeutic candidate, PrimeC, represents a groundbreaking extended-release oral formulation comprising a fixed-dose combination of two FDA-approved drugs, ciprofloxacin and celecoxib. Designed to target key ALS hallmarks such as microRNA synthesis, iron accumulation, and neuroinflammation, PrimeC has shown promising clinical efficacy in slowing disease progression. Expedited and de-risked regulatory pathway (orphan drug designation / 505(b)2 pathway). o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. Topline-results from the double-blind stage of the Phase2b trial shows robust clinical efficacy and safety profile, extended analysis is ongoing ahead of Phase 3 preparations. Ongoing Phase2 in AD and preclinical work in PD. These cover a substantial portion of the neurodegenerativediseases market, ranging a potential of \$20-40B USD. Future collaborations may include Sanofi, Merck, Novartis, Takeda, MT Pharma, Eli Lilly and more.

o Business Strategy Briefly describe how the company will apply its core technology, generate short-term and longterm revenues. The company intends to partner with Big Pharma to assist with marketing and distribution of the drug once it's approved.

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans NeuroSense is poised to advance its programs for AD, PD, and ALS while targeting expansion into the US market. The company is focused on securing funds through investments and collaborations to support its Phase 3 ALS trial and pursue further resources as it reaches key development milestones.